Overview

Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label Phase II clinical trial to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients with metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Collaborator:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel